CurASeal
Commercial- Indications
- Surgical bleeding, Hemorrhage control
Company intelligence / Profile preview
Curaseal has developed and commercialized a 100% plant-based starch hemostatic powder called CurASeal that rapidly controls bleeding during surgery. The product uses proprietary Nano-in-Microsphere technology with perforated microparticles to enable rapid clotting and full absorption within 48 hours. Clinical data show faster blood clotting than leading competitors like Arista and SURGICEL Powder. Additional pipeline products include multifunctional smart wound dressings and biocompatible stent coatings.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Curaseal.